Cibus and Loveland Products Collaborate to Develop and Sell Rice Traits in the US
- None.
- None.
Insights
The agreement between Cibus and Loveland Products signifies a strategic collaboration that aims to integrate advanced Non-GMO plant traits into Loveland's rice seed genetics. This partnership is particularly important for the agricultural sector as it focuses on addressing herbicide tolerance in rice, a critical issue for growers. The promise of accelerated trait integration using Cibus's Trait Machine™ technology could potentially shorten the development cycle of new seed varieties, allowing for quicker adaptation to market demands and farming challenges.
For investors, this collaboration could represent a long-term value proposition, as the development of herbicide-tolerant rice could lead to increased market share in the southern US, where weed management is a significant concern. The potential for Cibus's technology to be applied to other crops in the future could further expand the company's market opportunities and drive growth.
It is also worth noting that the focus on Non-GMO traits may appeal to a segment of consumers and regulators concerned with GMO crops, potentially providing a competitive edge in markets with such preferences.
The collaboration between Cibus and Loveland Products is poised to disrupt the rice seed market in the southern US. The emphasis on herbicide tolerance is a direct response to the prevalent weed management challenges faced by rice growers in the region. By leveraging Cibus's Trait Machine™, the partnership is expected to expedite the availability of improved rice varieties, which could lead to increased adoption rates among farmers seeking efficient and cost-effective solutions.
From a market perspective, the success of this collaboration could influence the competitive landscape, as other seed companies may need to innovate or form similar partnerships to stay relevant. This could result in increased R&D investments across the industry and potentially lead to a wave of new agricultural biotechnology advancements.
Moreover, the strategic partnership aligns with the growing trend of sustainable agriculture practices, as non-GMO, herbicide-tolerant crops can contribute to reduced environmental impact and align with regulatory trends favoring sustainable farming methods.
The announcement of the US Development Agreement between Cibus and Loveland Products could have significant financial implications for both companies. For Cibus, this deal represents a major commercial opportunity to showcase its Trait Machine™ technology's efficacy and commercial viability. Success in commercializing the herbicide-tolerant rice could lead to increased licensing revenue and a stronger position for future negotiations with other seed companies.
For Loveland Products and its parent company Nutrien Ltd., integrating cutting-edge traits into their seed offerings could enhance their product portfolio and potentially increase market share in the herbicide-tolerant seed market. This move could also reflect positively on Nutrien's stock performance on both the TSX and NYSE, especially if the market perceives the collaboration as a driver for future growth.
Investors should monitor the progress of this collaboration closely, as the development and commercialization of these rice varieties will likely be a multi-year process with financial benefits materializing in the medium to long term.
- Loveland Products has also agreed to collaborate with Cibus for future product development with its Dyna-Gro rice program
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses Non-GMO plant traits to seed companies, today announced that it has entered into a US Development Agreement with Loveland Products Inc., a subsidiary of Nutrien Ltd. (TSX and NYSE: NTR). Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland’s elite rice seed genetics.
Under the terms of the agreement Loveland and Cibus will work toward commercializing herbicide tolerance in rice with a focus on the southern US market, where demand for novel approaches in weed control is most prevalent.
“Loveland Products is constantly striving to bring innovative solutions to the marketplace across the agricultural industry,” says Rob Dunlop, Vice President of North America seed at Nutrien. “We are excited to collaborate with Cibus to help address some of the most pressing weed management challenges of US rice growers.”
“We are thrilled to work with the Loveland Products and Dyna-Gro teams to deliver new herbicide management options to rice growers,” stated Norm Sissons, Senior Vice President Commercial at Cibus. “Importantly, our recent results using our Trait MachineTM to add traits like herbicide tolerance in rice show we can provide collaborators with new traits in their elite genetics on an accelerated timescale.”
About the Cibus RTDS®-based High Throughput Breeding System
A key element of Cibus’ technology breakthrough is its High Throughput Breeding Process (referred to as the Trait Machine™ system). The Trait Machine process is a crop specific application of Cibus’ patented Rapid Trait Development System™ (RTDS®). The proprietary technologies in RTDS integrate crop specific cell biology platforms with a series of gene editing technologies to enable a system of end-to-end crop specific precision breeding. It is the core technology platform for Cibus’ Trait Machine: the first standardized end-to-end semi-automated crop specific gene editing system that directly edits a seed company’s elite germplasm. Each Trait Machine process requires a crop specific cell biology platform that enables Cibus to edit a single cell from a customers’ elite germplasm and grow that edited cell into a plant with the Cibus edits. Cibus has Trait Machine platforms developed for canola and rice and has already begun transferring their elite germplasm with Cibus edits back to customers.
The traits from Cibus’ RTDS-based High Throughput Breeding System are indistinguishable from traits developed using conventional breeding or from nature. RTDS does not integrate any foreign DNA or transgenes. Under the European Commission current proposals, it is expected that products from Cibus’ RTDS gene editing platform such as its pod shatter reduction trait and Sclerotinia resistance traits for Canola and Winter Oilseed Rape would be considered ‘Conventional-like'.
Cibus believes that RTDS and the Trait Machine process represent the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: High Throughput Gene Editing Systems operating as an extension of seed company breeding programs.
About Cibus
Cibus is a leader in Gene Edited Productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately
About Nutrien
Nutrien is a leading provider of crop inputs and services, helping to safely and sustainably feed a growing world. We operate a world-class network of production, distribution and ag retail facilities that positions us to efficiently serve the needs of growers. We focus on creating long-term value by prioritizing investments that strengthen the advantages of our integrated business and by maintaining access to the resources and the relationships with stakeholders needed to achieve our goals.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus’ operational and financial performance, Cibus’ strategy, future operations, prospects and plans, including the anticipated regulatory environment are forward-looking statements. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend,” “expect,” “plan,” “scheduled,” “could,” “would” and “will,” or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus’ management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus’ actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: changes in expected or existing competition; challenges to Cibus’ intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus’ platform or trait product development efforts; Cibus’ reliance on third parties in connection with its development activities; challenges associated with Cibus’ ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus’ traits or that farmers and processors fail to work effectively with crops containing Cibus’ traits; challenges that arise in respect of Cibus’ production of high-quality plants and seeds cost effectively on a large scale; Cibus’ need for additional funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; Cibus’ dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; Cibus’ ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus’ technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus’ ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in “Risk Factors of Cibus, Inc.” filed as Exhibit 99.3 with Cibus’ Current Report on Form 8-K, which was filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2023, as updated by the supplemental risk factors included in the Company's Current Reports on Form 8-K filed on October 18, 2023 and December 12, 2023, each as may be updated by any additional “Risk Factors” identified in Cibus’ subsequent reports on Forms 10-Q and 8-K filed with the SEC. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Cibus’ assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement and involves such risks and uncertainties. Accordingly, the Company could use its available capital resources sooner than it currently expects.
In addition, the forward-looking statements included in this press release represent Cibus’ views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus’ views as of any date subsequent to the date hereof.
CIBUS CONTACTS:
Investor Relations
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
Media Relations
Colin Sanford
colin@bioscribe.com
203-918-4347
NUTRIEN CONTACT:
Media Relations
Megan Fielding
megan.fielding@nutrien.com
403-225-7759
FAQ
What is the collaboration mentioned in the press release?
Who is involved in the collaboration with Cibus?
What market is the collaboration focusing on?
What technology is Cibus using for trait development?
Who commented on the collaboration from Loveland Products?
